Skip to main content
Tech.euFundingExplorerBeta

NovImmune

Develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders

NovImmune has raised €192M across 7 funding rounds from 7 investors, most recently a Series D+ round in Jan 2016. Based in Plan-les-Ouates, Switzerland; founded 1998; active in Healthtech. Data as of 28 Oct 2026.

Plan-les-Ouates, SwitzerlandFounded 1998novimmune.com ↗
Healthtech
← All companies
Total raised
€192M
€191,502,647
Funding rounds
7
Investors
7
distinct backers
Active since
2000-05
latest 2016-01

Funding by year

EUR raised per year
NovImmune — funding by year — interactive chart.
Data table
NovImmune — funding by year
2000€15M
2006€36M
2009€41M
2010€17M
2012€6.0M
2014€49M
2015€27M

Signals

Medium confidence
Raise-next likelihood9
base rate 53% for Series D+
  • ▼ Dormant (no round in 3+ cohort gaps)
  • ▼ Down/flat last round
Exit likelihood8
base rate 11% (2+ rounds)
  • ▲ €100M+ raised
  • ▲ 7 rounds raised
  • ▼ Old (28y) — past typical exit age
  • ▼ No recent equity round (debt-only or quiet)

Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

7 rounds
DateStageAmountInvestors
2016-01-01Series D+€27M—View deal →
2014-02-01Series D+€49MRosetta CapitalView deal →
2012-10-01Grant€6.0M—View deal →
2010-12-01Series D+€17MBZ BankView deal →
2009-05-01Series C€41MAravis Ventures,BZ Bank,LODH Immunology Fund,Novartis Venture Fund,Pictet,VarumaView deal →
2006-06-01Series B€36MAravis Ventures,LODH Immunology Fund,Novartis Venture Fund,PictetView deal →
2000-05-01Series A€15MLODH Immunology Fund,Novartis Venture FundView deal →

Investors

7
Aravis VenturesBZ BankLODH Immunology FundNovartis Venture FundPictetRosetta CapitalVaruma

Related news

Similar companies

same sector or country

Global coverage: FundingData